17,261 trials
Asthma
Primary: Trough Forced Expiratory Volume in One Second (FEV1) After 7 Days of Treatment — 2.84; 2.83; 2.80; 2.64 Liters
Wounds
Primary: Complete Wound Closure — 14.8; 14.9 days
Moderate to Severe COPD
Primary: FEV1 — 0.007; 0.011 L
Colorectal Cancer · Metastases
Primary: Objective Tumor Response Through Week 16 — 6 participants
Advanced Malignant Mesothelioma · Localized Malignant Mesothelioma · Recurrent Malignant Mesothelioma
Primary: Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST) — 47.8 percentage of…
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Complete Response — 24; 29 participants
Stage IV Pancreatic Cancer
Primary: Maximum Tolerated Dose Determination — 6 mg/kg IMC-A12
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage IV Pancreatic Cancer
Primary: Six Month Survival — 11 percentage of patients
Obesity
Primary: LS Mean Percent Change in Body Weight From Original Study DFA102 (NCT00673387) Baseline (Day 1) at Week 52 in Extension Study DFA102E - Evaluable Treatment Stable…
Hormone Refractory Prostate Cancer · Recurrent Prostate Cancer
Primary: 12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2) — 2; 8 participants
Macular Edema · Retinal Vein Occlusion
Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters
Desmoid Tumor
Primary: Percentage of Patients Failure Free at 2 Years Following Study Entry — 36 percentage of participants
Human Immunodeficiency Virus (HIV)
Primary: Number of Participants With Confirmed Virologic Response (CVR) at Week 48 — 40 Participants
Secondary Hyperparathyroidism
Primary: Change From Baseline to End of Study in Bone Formation Rate (BFR) — -488 μm^2/mm^2/day
Acne Vulgaris
Primary: Percentage Change in Inflammatory Lesions From Baseline to End of Treatment — -20.3; -29.4 percentage of change